<DOC>
	<DOCNO>NCT00917449</DOCNO>
	<brief_summary>Aim The principal objective project : â€¢ To evaluate efficacy long term ( 18 month ) L-Arginine therapy prevent delay clinical onset type 2 diabetes mellitus subject impair glucose tolerance ( IGT ) Metabolic Syndrome . Secondary end point : 1 . To define long term treatment L-arginine able ameliorate insulin sensitivity endothelial dysfunction population . 2 . To find new risk profile candidate gene able define sub-group patient high risk develop type 2 diabetes mellitus . Methodology This double blind , parallel , one centre study determine long term oral L-arginine administration able delay prevent type 2 diabetes mellitus patient Metabolic Syndrome . Two hundred ninety four subject recruit Cardio-Metabolic Clinical Trials Unit San Raffaele Scientific Institute . One hundred forty two patient randomize enter study assign two arm : oral L-arginine ( 6.4 g/die ) placebo , addition diet physical exercise . The treatment maintain 18 month . Visits perform every 3 month clinical evaluation , blood sample , treatment supply collection data adverse event . Furthermore , patient contact every month telephone evaluate accurate continuation study instruct phone centre case possible adverse event . An OGTT perform enter study end study period . An additional OGTT perform intermediate visit fast glucose level 126 mg/dl . A diabetic response cause end-point patient . Metabolic , hormonal endothelial activation inflammation parameter measure . Evaluation endothelium-mediated non-endothelium-mediated vasodilatation perform strain gauche plethysmography evaluate forearm blood basal state . post-ischemic condition nitroglycerine administration . Before enter study , additional blood sample drawn DNA extraction candidate gene variant evaluation . Before enter study end study period , gene expression inflammation measure mRNA extraction endothelial progenitor cell .</brief_summary>
	<brief_title>Prevention Type 2 Diabetes Mellitus L-Arginine Patients With Metabolic Syndrome</brief_title>
	<detailed_description>This double blind , parallel , one centre study determine long term oral L-arginine administration able delay prevent type 2 diabetes mellitus patient IGT Metabolic Syndrome . Two hundred ninety four subject recruit CardioMetabolic Clinical Trials Unit San Raffaele Scientific Institute . One hundred fourty two patient randomize enter study . Patients randomly assign two arm : oral L-arginine ( 6.4 g/die ) placebo blind scheme . The treatment maintain 18 month . Visits perform every 3 month clinical evaluation , blood sample , treatment supply collect data adverse event , . Furthermore , patient contact every month telephone evaluate accurate continuation study instruct phone centre case possible adverse event . Inclusion criterion - Written informed consent must obtain procedure study do . - Male Female age 35 year . - Diagnosis IGT standard Glucose Tolerance Test ( OGTT , 75 g ) - Moreover , order consider affected Metabolic Syndrome , must two follow criterion : - Abdominal obesity ( waist &gt; 120 cm man , &gt; 88 cm woman ) - Hypertriglyceridemia ( &gt; 150 mg/dl ) - Low HDL cholesterol ( &lt; 40mg/dl man , &lt; 50 mg/dl woman ) - Hypertension ( &gt; 130 / &gt; 85 mmHg ) Exclusion criterion - Presence type 1 type 2 diabetes mellitus - Fasting glucose level &gt; 126 mg/dl - Sitting Systolic Arterial Pressure &gt; 140mmHg , Sitting Diastolic Arterial Pressure &gt; 90mmHg - Pregnancy - Known renal insufficiency creatinine level 1.8 mg/dl , - Presence chronic hepatopathy level ALT AST two standard deviation normality level - Presence malignancy - Abuse alcohol abuse substances - Psychiatric disorder</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Written informed consent must obtain procedure study do . Male Female age 35 year . Diagnosis IGT standard Glucose Tolerance Test ( OGTT , 75 g ) Moreover , order consider affected Metabolic Syndrome , must two follow criterion : Abdominal obesity ( waist &gt; 120 cm man , &gt; 88 cm woman ) Hypertriglyceridemia ( &gt; 150 mg/dl ) Low HDL cholesterol ( &lt; 40mg/dl man , &lt; 50 mg/dl woman ) Hypertension ( &gt; 130 / &gt; 85 mmHg ) Presence type 1 type 2 diabetes mellitus Fasting glucose level &gt; 126 mg/dl Sitting Systolic Arterial Pressure &gt; 140mmHg , Sitting Diastolic Arterial Pressure &gt; 90mmHg Pregnancy Known renal insufficiency creatinine level 1.8 mg/dl , Presence chronic hepatopathy level ALT AST two standard deviation normality level Presence malignancy Abuse alcohol abuse substance Psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>L-arginine</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>